Liquid protein formulations for injection comprising 1-butyl-3-methylimidazolium methanesulfonate and uses thereof
Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.
1. A liquid pharmaceutical formulation for injection comprising:
(i) an antibody;
(ii) about 0.4 M to about 0.5 M of 1-butyl-3-methylimidazolium methanesulfonate (BMI-Mes); and
(iii) a pharmaceutically acceptable solvent;
wherein the liquid pharmaceutical formulation, when in a volume suitable for injection, has an absolute viscosity from about 1 cP to about 100 cP at 25° C. as measured using a cone and plate viscometer or a microfluidic viscometer; and the absolute viscosity of the liquid pharmaceutical formulation is less than the absolute viscosity of a liquid pharmaceutical formulation comprising the antibody and the pharmaceutically acceptable solvent, but with an equivalent amount of sodium phosphate in place of the BMI-Mes; and
wherein the absolute viscosity is an extrapolated zero-shear viscosity.
2. The liquid pharmaceutical formulation of claim 1 , wherein the antibody has a molecular weight of from about 120 kDa to about 250 kDa.
3. The liquid pharmaceutical formulation of claim 1 , wherein the antibody is present in an amount of from about 180 mg to about 232 mg per 1 mL (mg/mL).
4. The liquid pharmaceutical formulation of claim 1 , wherein the liquid pharmaceutical formulation is aqueous having a pH between about 5.0 and about 8.0.
5. The liquid pharmaceutical formulation of claim 1 , comprising one or more pharmaceutically acceptable excipients for subcutaneous or intramuscular injection comprising a sugar, sugar alcohol, buffering agent, preservative, carrier, antioxidant, chelating agent, natural polymer, synthetic polymer, cryoprotectant, lyoprotectant, surfactant, bulking agent, stabilizing agent, or any combination thereof.
6. The liquid pharmaceutical formulation of claim 5 , wherein one or more of the excipients is a polysorbate, poloxamer 188, sodium lauryl sulfate, a polyol, a poly(ethylene glycol), glycerol, a propylene glycol, or a poly(vinyl alcohol).
7. The liquid pharmaceutical formulation of claim 5 , wherein the surfactant is present in an amount less than about 10 mg/mL.
8. The liquid pharmaceutical formulation of claim 6 , wherein the polyol is present in an amount from about 2 mg/mL to about 900 mg/mL.
9. The liquid pharmaceutical formulation of claim 1 , wherein the absolute viscosity of the liquid pharmaceutical formulation is at least about 30% less than the absolute viscosity of a formulation comprising the antibody, the pharmaceutically acceptable solvent, and an appropriate buffer in place of the BMI-Mes, wherein the buffer is present at about the same concentration as the BMI-Mes.
10. The liquid pharmaceutical formulation of claim 1 in a unit-dose vial, cartridge, container, or pre-filled syringe.
11. The liquid pharmaceutical formulation of claim 1 , having a volume of less than about 1.5 mL for subcutaneous (SC) injection, or less than about 3 mL for intramuscular (IM) injection.
12. The liquid pharmaceutical formulation of claim 1 , wherein the liquid pharmaceutical formulation is isotonic to human blood serum.
13. The liquid pharmaceutical formulation of claim 1 , wherein the absolute viscosity of the liquid pharmaceutical formulation is measured at a shear rate of at least about 0.5 s −1 , when measured using a cone and plate viscometer.
14. The liquid pharmaceutical formulation of claim 1 , wherein the absolute viscosity of the liquid pharmaceutical formulation is measured at a shear rate of at least about 1.0 s −1 , when measured using a microfluidic viscometer.
15. A method of administering to a subject a therapeutically effective amount of an antibody comprising subcutaneously or intramuscularly injecting the liquid pharmaceutical formulation of claim 1 into the subject.
16. The method of claim 15 , wherein the injecting is performed with a syringe.
17. The method of claim 16 , wherein the syringe is a heated syringe and the liquid pharmaceutical formulation has a temperature between 25° C. and 40° C.
18. The method of claim 15 , wherein the injecting the liquid pharmaceutical formulation produces a primary irritation index of less than 3 when evaluated using a Draize scoring system.
19. The method of claim 15 , wherein the injecting has an injection force that is at least 10% less than an injection force for a liquid pharmaceutical formulation comprising the antibody and the pharmaceutically acceptable solvent, but without the BMI-Mes, when administered in the same way.
20. The method of claim 15 , wherein the injecting is performed with a needle between 27 and 31 gauge in diameter and the injection force is less than 30 N with the 27 gauge needle.
21. A method of preparing the liquid pharmaceutical formulation of claim 1 comprising the step of combining the antibody, the pharmaceutically acceptable solvent, and the BMI-Mes.
22. The liquid pharmaceutical formulation of claim 1 , wherein the antibody is a monoclonal antibody.
23. The liquid pharmaceutical formulation of claim 6 , wherein the polyol is a sugar alcohol.
24. The liquid pharmaceutical formulation of claim 23 , wherein the sugar alcohol is sorbitol or mannitol.
25. The method of claim 16 , wherein the syringe is a heated syringe, a self-mixing syringe, an auto-injector, a pre-filled syringe, or combinations thereof.
26. The method of claim 19 , wherein the injecting has an injection force that is 20% less than an injection force for a liquid pharmaceutical formulation comprising the antibody and the pharmaceutically acceptable solvent, but without the BMI-Mes, when administered in the same way.